Introducing a Therapeutic Option in R/R NPM1m Acute Myeloid Leukemia
Date: Tuesday, January 6 | 2 p.m. EST
Presenter: Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC | Minnesota Oncology
Relapsed/refractory NPM1-mutated acute myeloid leukemia brings important clinical decisions around treatment selection, timing, and implementation. Understanding how a therapeutic option fits into care is critical for teams managing these patients.
In this session, Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, of Minnesota Oncology, reviews a therapeutic option for R/R NPM1m AML with a focus on patient considerations, dosing and administration, and how it is incorporated into clinical practice.
Key Takeaways:
- Understand the unmet need in relapsed/refractory NPM1m acute myeloid leukemia
- Discuss the clinical profile of a therapeutic option in relapsed/refractory NPM1m acute myeloid leukemia
- Gain a thorough understanding of dosing, administration, and practical implications
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
Upcoming Webinar
Introducing a Therapeutic Option in R/R NPM1m Acute Myeloid Leukemia
January 6, 2026 | 2:00 PM
